Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

05:30 EDT 23rd August 2014 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 17,000+

Extremely Relevant

[Comment] Cetuximab or bevacizumab in metastatic colorectal cancer?

In The Lancet Oncology, Volker Heinemann and colleagues report the results of FIRE-3, a randomised phase 3 trial comparing cetuximab with bevacizumab, in combination with fluorouracil, folinic acid, and irinotecan (FOLFIRI), for the first-line treatm...

ESMO GI: Cetuximab or bevacizumab with combi chemo equivalent in KRAS wile-type metastic colorectal cancer

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. “The...

Cetuximab delivers better overall survival than bevacizumab in metastatic colorectal cancer

by ecancer reporter Janet Fricker Patients with KRAS exon 2 wild type metastatic colorectal cancer achieve longer overall survival with FOLFIRI plus cetuximab than FOLFIRI plus bevacizumab, concluded the FIRE-3 trial published in Lancet Oncology. W...

ASCO 2014: First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

Results from a large federally funded phase III study demonstrate that four common first-line treatment regimens – bevacizumab plus chemotherapy and cetuximab plus chemotherapy – are equally effective for patients with metastatic colorectal cance...

[Articles] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Although the proportion of patients who achieved an objective response did not significantly differ between the FOLFIRI plus cetuximab and FOLFIRI plus bevacizumab groups, the association with longer overall survival suggests that FOLFIRI plus cetuxi...

Bevacizumab, Cetuximab Have Similar Survival Benefits in CRC

Adding either bevacizumab or cetuximab to chemotherapy yielded equal benefits in metastatic colorectal cancer (CRC). Medscape Medical News

[News] NICE guidance on aflibercept for treatment of metastatic colorectal cancer

On March 25, 2014, the National Institute for Health and Care Excellence (NICE) published guidance that did not recommend aflibercept with irinotecan and fluorouracil-based therapy (hereafter termed aflibercept) for treatment of metastatic colorectal...

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC

(European Society for Medical Oncology) For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastroin...

From ASCO—colorectal cancer: Cetuximab or bevacizumab with chemo: take your pick

ASCO: Chemo Plus Avastin or Erbitux Boosts Colorectal Ca Survival

CHICAGO (MedPage Today) -- Treatment with either cetuximab or bevacizumab and standard chemotherapy produced a median survival of about 2.5 years among patients with advanced metastatic colorectal cancer, according to results of a long-term clinical...

Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab

First-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy provide similar survival benefit for patients with metastatic colorectal cancer

At a press conference at ASCO 2014, Dr Venook presents the results from a large federally funded phase III study which demonstrate that four common first-line treatment regimens – bevacizumab plus chemotherapy and cetuximab plus chemotherapy – ar...

Biosimilars of bevacizumab

Bevacizumab is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in t...

Important facts about colorectal cancer

Colorectal cancer is the fourth most common cancer in the U.S., with about 143,000 new patients diagnosed last year. But thanks to increased awareness about screenings, the death rate from colorectal cancer has been dropping for more than 20 years.

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

Genetic testing of tumor is recommended for colorectal cancer patients

Of the 143,000 patients diagnosed with colorectal cancer annually in the U.S., up to 25 percent have a familial risk of colorectal cancer. A new guideline from the U.S. Multi-Society Task Force on Colorectal Cancer recommends genetic testing of tumor...

Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer

Chemotherapy Regimens paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer

In a plenary session of the American Society of Clinical Oncology (ASCO) meeting in Chicago, researchers reported that treatment of metastatic colorectal cancer with Avastin® (bevacizumab) or Erbitux® (cetuximab) and standard chemotherapy (FOLFOX o...

FDA OKs Bevacizumab (Avastin) for Late-Stage Cervical Cancer

The new indication for bevacizumab includes patients with cervical cancer that is persistent or recurrent. FDA Approvals

New guideline recommends genetic testing of tumors for colorectal cancer patients

Of the 143,000 patients diagnosed with colorectal cancer annually in the U.S., up to 25 percent have a familial risk of colorectal cancer. A new guideline from the U.S. Multi-Society Task Force on Colorectal Cancer recommends genetic testing of tumor...

Gut microbes may play a role in colorectal cancer

New research from the US suggests an individual's particular mix of gut microbes may help the development of colorectal cancer tumors by interacting with genes and inflammatory responses.Colorectal cancer happens because healthy cells in the gut star...

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic cancer that had progressed on Gemzar® (ge...

Address the racial disparity of colorectal cancer

An article published recently in the American Cancer Society journal CA: A Journal for Clinicians received a lot of media attention. The report showed dramatic declines in the rate of people being diagnosed with colorectal cancer, as well as decreases in the rates of colorectal cancer deaths over the past number of years. Continue reading ... Your patients are rating you online: How [̷...

Likely key driver of colorectal cancer development, progression

A molecule that is a probable driving force in colorectal cancer has been identified in a new study. The molecule could be an important target for colorectal cancer treatment and a valuable biomarker of tumor progression. The researchers demonstrate...

NICE issues final no for Sanofi's Zaltrap

NICE assessed Zaltrap in combination with irinotecan and fluorouracil-based therapy (FOLFIRI) for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy. The institute, which conducts health technolog...


Search BioPortfolio:
Advertisement
Advertisement

News Quicklinks